What is ACE-083?
ACE-083 is a follistatin-based investigational protein designed to act locally on muscle-regulatory pathways. The clinical molecule is more specific than the general label 'myostatin inhibitor.'
Mechanism & research focus
It binds myostatin and other muscle regulators in the TGF-β family, aiming to reduce signals that restrain muscle growth. Increased tissue volume is a pharmacodynamic outcome, not necessarily improved muscle function.
What the research covers
A phase 1 study reported local muscle-volume increases without significant strength changes. In a 2022 randomized phase 2 study in facioscapulohumeral muscular dystrophy, increased muscle volume again did not produce consistent functional or patient-reported benefits.
What remains uncertain
The negative functional findings are central to interpretation. These trials do not establish general performance enhancement or validate a commercial research solution. Identity, protein integrity and biological activity require separate analytical confirmation.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Locally acting ACE-083 increases muscle volume in healthy volunteers ↗
Follistatin-based mechanism and local muscle-volume findings; strength did not significantly improve.
Randomized phase 2 study of ACE-083 in facioscapulohumeral muscular dystrophy ↗
Greater muscle volume did not translate into consistent functional or patient-reported improvement.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: ACE-083 research guide ↗